Simply because we want one thing to speak about that is not mega tech…
VRTX put in one other sturdy quarter. 18% y/y income development. GAAP earnings up 9%. Additionally with a slight increase to ahead steering. Additionally of be aware, they’ve $9.8 billion in money and no debt. This places them in an attention-grabbing place ought to a variety of begin up biotech corporations begin working out of cash.
Additionally attention-grabbing, they’ve 2 medication in last testing levels, one for sickle cell illness and one one for ache. They’ve already employed employees to get these medication quicky to market.
https://finance.yahoo.com/information/vertex-reports-third-quarter-2022-200100403.html
Full disclosure I personal shares of VRTX and it has been a beast this yr.
